LASTACAFT

This brand name is authorized in United States. It is also authorized in Brazil, Ecuador, Mexico, Singapore, Turkey.

Active ingredients

The drug LASTACAFT contains one active pharmaceutical ingredient (API):

1	Alcaftadine UNII 7Z8O94ECSX - ALCAFTADINE
	Alcaftadine is an H1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.
	Read more about Alcaftadine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LASTACAFT Solution (Drops)	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01GX11		S Sensory organs → S01 Ophthalmologicals → S01G Decongestants and antiallergics → S01GX Other antiallergics
Discover more medicines within S01GX11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	501012030011902
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	1605-MEE-1215
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	141M2013
SG	Health Sciences Authority	14297P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699490561300
US	FDA, National Drug Code	0023-4290